Gastrointestinal Cancer

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

By

The FDA based its approval on evidence from the ongoing, non-randomized CheckMate-142 phase 2 study, for which researchers treated 119 patients with nivolumab plus ipilimumab.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Colon Cancer Screening: American Cancer Society Guidelines Update

Colon Cancer Screening: American Cancer Society Guidelines Update

By

An increase in the appearance of colorectal cancer incidence in younger people has prompted the American Cancer Society to revise its current screening guidelines.

Real-World Study Reports PFS and OS in Metastatic CRC

Real-World Study Reports PFS and OS in Metastatic CRC

By

A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.

Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer

Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer

By

Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.

Benefit of Ramucirumab in Relapsed Hepatocellular Carcinoma Confirmed in Pooled Analysis

Benefit of Ramucirumab in Relapsed Hepatocellular Carcinoma Confirmed in Pooled Analysis

By

Ramucirumab prolonged progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory hepatocellular carcinoma (HCC).

Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer

Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer

By

CORRECT and CONCUR trials demonstrated an improvement in OS for patients receiving regorafenib compared with placebo.

Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy

Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy

By

Researchers sought to determine if autophagy-related proteins are associated with survival among patients with CRC.

Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer

Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer

By

A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.

Capecitabine-Activating Enzyme Levels Prognostic for Metastatic Gastric Cancer Outcomes

Capecitabine-Activating Enzyme Levels Prognostic for Metastatic Gastric Cancer Outcomes

By

XP-treated patients with metastatic gastric cancer who had tumors expressing UCK2 and OPRT above a specific threshold survived longer than patients with lower levels of these biomarkers.

Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites

Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites

By

In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.

No Benefit With Addition of EGFR Inhibitor to Chemotherapy in Esophageal Cancer

No Benefit With Addition of EGFR Inhibitor to Chemotherapy in Esophageal Cancer

By

The addition of an EGFR inhibitor to a chemotherapy regimen did not improve outcomes when it came to cancers of the esophagus.

Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer

Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer

By

The CRICKET trial is evaluating the third-line retreatment of patients with mCRC with cetixumab plus irinotecan.

Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC

Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC

By

Increasing the sensitivity cutoff from 5% to 1% in next-generation sequencing allowed for the identification of 28% more RAS/BRAF mutations.

Baseline Appetite Associated With Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma

Baseline Appetite Associated With Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma

By

A study reported post-hoc subgroup analyses of the international phase 3 NAPOLI-1 trial.

Liquid Biopsy Test Accurately Detects <i>RAS</i> Mutations in Metastatic Colorectal Cancer

Liquid Biopsy Test Accurately Detects RAS Mutations in Metastatic Colorectal Cancer

By

The OncoBEAM RAS kit for circulating tumor DNA (ctDNA) analysis of patients with metastatic colorectal cancer (mCRC) demonstrated high positive and negative agreement of RAS mutations detected by tumor tissue analysis.

Better Quality of Life With Nab-Paclitaxel Added to Gemcitabine in Pancreatic Cancer

Better Quality of Life With Nab-Paclitaxel Added to Gemcitabine in Pancreatic Cancer

By

The combination of nab-paclitaxel plus gemcitabine improved quality of life scores and increased time to deterioration compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Adding Oxaliplatin to Capecitabine-Based Chemotherapy, Radiation May Not Improve Survival in Rectal Cancer

Adding Oxaliplatin to Capecitabine-Based Chemotherapy, Radiation May Not Improve Survival in Rectal Cancer

By

Researchers randomly assigned 1090 patients with advanced rectal adenocarcinoma to 5 weeks of preoperative capecitabine-based chemoradiation followed by 6 cycles of capecitabine alone or with oxaliplatin.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

By

There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Hepatocellular Carcinoma Treatment Regimens

Find cancer treatment regimens for hepatocellular carcinoma, including drugs such as sorafenib (Nexavar) and chemotherapy/radiotherapy clinical trials.

Patients with advanced adenomas are at increased risk of developing colorectal cancer

In this randomized screening trial, patients with advanced adenomas detected by flex sigmoidoscopy (FSG) were at significantly increased risk of CRC compared to those with no adenomas.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Nodal Response to Neoadjuvant Therapy Predictive of Survival in Esophageal Cancer

Nodal Response to Neoadjuvant Therapy Predictive of Survival in Esophageal Cancer

By

Findings on the predictive nature of nodal response to neoadjuvant therapy from the American Association for Thoracic Surgery 98th Annual Meeting.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs